These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28567571)

  • 1. Atypical acute motor axonal neuropathy following alemtuzumab treatment in multiple sclerosis patient.
    Hradilek P; Woznicova I; Slonkova J; Lochmanova A; Zeman D
    Acta Neurol Belg; 2017 Dec; 117(4):965-967. PubMed ID: 28567571
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.
    Haghikia A; Dendrou CA; Schneider R; Grüter T; Postert T; Matzke M; Stephanik H; Fugger L; Gold R
    Lancet Neurol; 2017 Feb; 16(2):104-106. PubMed ID: 28102146
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.
    McCaughan G; Massey J; Sutton I; Curnow J
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29212866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.
    Sprangers B; Decoo D; Dive D; Lysandropoulos A; Vanopdenbosch L; Bovy C
    Acta Neurol Belg; 2018 Jun; 118(2):143-151. PubMed ID: 29189966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.
    Frau J; Coghe G; Fenu G; Lorefice L; Cocco E
    Neurol Sci; 2018 Feb; 39(2):389-390. PubMed ID: 28986705
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH
    Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462
    [No Abstract]   [Full Text] [Related]  

  • 9. [Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy].
    Mike A; Kincses ZT; Vécsei L
    Ideggyogy Sz; 2017 Jan; 70(1-2):15-24. PubMed ID: 29870189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis.
    Madeley J; Hodges G; Birchley A
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30337289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
    Scappaticcio L; Castellana M; Virili C; Bellastella G; Centanni M; Cannavò S; Campennì A; Ruggeri RM; Giovanella L; Trimboli P
    J Endocrinol Invest; 2020 Feb; 43(2):219-229. PubMed ID: 31452116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.
    Bolte FJ; Schmidt HH; Schlevogt B
    Hepatology; 2021 Jan; 73(1):460-463. PubMed ID: 32583445
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT.
    Cipolla G; Relo R; Pasciuta E; Catalano D; Lo Bello F; Coppolino I; Ruggeri P; Proietto A; Buccafusca M; Cutroneo PM; Trifirò G; Caramori G
    Monaldi Arch Chest Dis; 2020 Jul; 90(3):. PubMed ID: 32702962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Desensitization to Alemtuzumab, With Flow Cytometry Analysis of Peripheral Blood Cells.
    Costa Carvalho J; Macário MC; Batista S; Alen Coutinho I; Laranjeira P; Loureiro C; Paiva A; Todo Bom A
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):501-503. PubMed ID: 35225791
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of acute fulminant multiple sclerosis treated with alemtuzumab.
    Gobbin F; Marangi A; Orlandi R; Richelli S; Turatti M; Calabrese M; Forgione A; Alessandrini F; Benedetti MD; Monaco S; Gajofatto A
    Mult Scler Relat Disord; 2017 Oct; 17():9-11. PubMed ID: 29055482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Subclinical lesions of peripheral nervous system in multiple sclerosis patients].
    Pogorzelski R; Baniukiewicz E; Drozdowski W
    Neurol Neurochir Pol; 2004; 38(4):257-64. PubMed ID: 15383952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.